GABAB Receptors in Neurodegeneration

Alessandra P Princivalle

doi:10.1007/7854_2021_222

GABA_B Receptors in Neurodegeneration

Curr Top Behav Neurosci. 2022:52:267-290. doi: 10.1007/7854_2021_222.

Author

Alessandra P Princivalle¹

Affiliation

¹ Department of Bioscience and Chemistry, Biomolecular Research Centre, College of Health, Wellbeing and Life Sciences at Sheffield Hallam University, Sheffield, UK. a.p.princivalle@shu.ac.uk.

PMID: 33728599
DOI: 10.1007/7854_2021_222

Abstract

GABA is the main inhibitory neurotransmitter in the mammalian central nervous system (CNS) and acts via metabotropic GABA_B receptors. Neurodegenerative diseases are a major burden and affect an ever increasing number of humans. The actual therapeutic drugs available are partially effective to slow down the progression of the diseases, but there is a clear need to improve pharmacological treatment thus find alternative drug targets and develop newer pharmaco-treatments. This chapter is dedicated to reviewing the latest evidence about GABA_B receptors and their inhibitory mechanisms and pathways involved in the neurodegenerative pathologies.

Keywords: Alzheimer’s disease; GABAB receptors; Hippocampal sclerosis; Neurodegenerative diseases; Parkinson’s disease; Temporal lobe epilepsy.

MeSH terms

Animals
Central Nervous System
Humans
Neurodegenerative Diseases*
Receptors, GABA-B*
gamma-Aminobutyric Acid

Substances

Receptors, GABA-B
gamma-Aminobutyric Acid